A 46-year-old patient presented for a second opinion on a mass found within the right breast on a prior outside mammogram. The patient denies any lumps or pain within either breast.
A 46-year-old patient presented for a second opinion on a mass found within the right breast on a prior outside mammogram. The patient denies any lumps or pain within either breast.
Mammography reveals an irregular spiculated mass in the right superior breast, measuring 1.6 cm in diameter (Figures 1 and 2).
On physical exam, no palpable lump is found. On ultrasound, a hypoechoic mass is present within the right 12:00 area measuring 1.0 x 0.8 cm (Figure 3).
MR imaging performed for extent of disease demonstrates the known carcinoma measuring 1.8 cm in the right breast as well as an additional enhancing mass within the left breast (Figure 4). The patient is recalled for second-look ultrasound as well as possible MRI-guided needle biopsy.
At targeted ultrasound the new mass detected on MRI in the left breast is found to measure 8 mm in diameter (Figure 5). The patient consented to undergo ultrasound-guided needle biopsy.
Vacuum-assisted needle core biopsy of the right breast 12:00 area reveals invasive ductal carcinoma. Ultrasound-guided biopsy of the additional mass in the left breast reveals well-differentiated invasive ductal carcinoma. The patient then proceeded to have bilateral lumpectomies.
This case demonstrates the benefit of a complete work-up, including MRI, after diagnosis of breast cancer and the benefit that targeted ultrasound can have in evaluating unsuspected abnormalities found on MRI. The new lesion found on MRI was identified by targeted ultrasound and was therefore able to be biopsied under ultrasound guidance. This is beneficial to both the patient and the facility as the ultrasound procedure is quick and comfortable.
Dr. Destounis is managing partner and a radiologist at Elizabeth Wende Breast Care in Rochester, NY.
Abbreviated MRI for Hepatocellular Carcinoma: What a New Meta-Analysis Reveals
January 6th 2025For hepatocellular carcinoma screening, a 19-study meta-analysis found the abbreviated MRI sequencing protocol of T2-weighted MRI, diffusion-weighted imaging (DWI) and hepatobiliary phase (HBP) imaging offered 88 percent sensitivity and 93 percent specificity.
Study Emphasizes PSMA PET Staging of High-Risk, Hormone Sensitive Prostate Cancer
January 4th 2025In patients with high-risk, hormone sensitive prostate cancer who had no evidence of metastasis on conventional imaging, PSMA PET revealed polymetastatic disease in 24 percent of patients and M1 disease staging in 46 percent of patients.
Can MRI and Micro-Ultrasound Guidance Bolster Focal Laser Ablation Outcomes for Prostate Cancer?
January 3rd 2025For patients with localized prostate cancer and PI-RADS 3 or higher lesions, MRI-guided micro-ultrasound multifiber focal laser ablation had an 18 percent recurrence rate at one year, according to newly published research.
New CT and MRI Research Shows Link Between LR-M Lesions and Rapid Progression of Early-Stage HCC
January 2nd 2025Seventy percent of LR-M hepatocellular carcinoma (HCC) cases were associated with rapid growth in comparison to 12.5 percent of LR-4 HCCs and 28.5 percent of LR-4 HCCs, according to a new study.